The quest for vaccines and therapeutics against COVID-19 has driven together institutions, companies, countries and scientific communities. Rivals have become partners and R&D timelines have shrunk: just 10 months following the publication of the viral gene-sequence for SARS-CoV-2, 11 vaccine candidates had started Phase III trials. By mid November 2020, highly promising efficacy results had emerged from two of those vaccines, including a vaccine candidate from partners Pfizer Inc. and BioNTech SE.
Data-sharing has expanded, between and among companies and academic institutions, and efforts have grown to integrate disparate data sources, including...



